Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.51 |
| ▸ | HTR3A | P46098 | 5/20 | 0.51 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.39 |
| ▸ | HTR3B | O95264 | 2/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057396 | 0.85 | HTR3A (0.48) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL23160982 | 0.83 | DPP4 (0.41) | HRH4METKDM4EALDH1A1HRH3 | |
| SCHEMBL23160996 | 0.83 | CDK4 (0.35) | HRH4HTR3AKDM4EALDH1A1 | |
| SCHEMBL23161886 | 0.83 | LCK (0.38) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17255067 | 0.82 | HRH4 (0.52) | HRH4HTR3AMETKDM4E | |
| SCHEMBL23160988 | 0.82 | DPP4 (0.38) | — | |
| SCHEMBL23161884 | 0.82 | HRH1 (0.42) | HRH4HRH3 | |
| SCHEMBL17255017 | 0.82 | HRH4 (0.44) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL20078423 | 0.81 | HTR3A (0.50) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17255050 | 0.79 | HRH4 (0.51) | HRH4HTR3AMETHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094952-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094952-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885HTR3A 4237/4885MET 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.